Antioxidants and NOX1/NOX4 inhibition blocks TGFβ1-induced CCN2 and α-SMA expression in dermal and gingival fibroblasts

PLoS One. 2017 Oct 19;12(10):e0186740. doi: 10.1371/journal.pone.0186740. eCollection 2017.

Abstract

TGFbeta induces fibrogenic responses in fibroblasts. Reactive oxygen species (ROS)/nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) may contribute to fibrogenic responses. Here, we examine if the antioxidant N-acetylcysteine (NAC), the NOX inhibitor diphenyleneiodonium (DPI) and the selective NOX1/NOX4 inhibitor GKT-137831 impairs the ability of TGFbeta to induce profibrotic gene expression in human gingival (HGF) and dermal (HDF) fibroblasts. We also assess if GKT-137831 can block the persistent fibrotic phenotype of lesional scleroderma (SSc) fibroblasts. We use real-time polymerase chain reaction and Western blot analysis to evaluate whether NAC and DPI impair the ability of TGFbeta1 to induce expression of fibrogenic genes in fibroblasts. The effects of GKT-137831 on TGFbeta-induced protein expression and the persistent fibrotic phenotype of lesional scleroderma (SSc) fibroblasts were tested using Western blot and collagen gel contraction analyses. In HDF and HGF, TGFbeta1 induces CCN2, CCN1, endothelin-1 and alpha-smooth muscle actin (SMA) in a fashion sensitive to NAC. Induction of COL1A1 mRNA was unaffected. Similar results were seen with DPI. NAC and DPI impaired the ability of TGFbeta1 to induce protein expression of CCN2 and alpha-SMA in HDF and HGF. GKT-137831 impaired TGFbeta-induced CCN2 and alpha-SMA protein expression in HGF and HDF. In lesional SSc dermal fibroblasts, GKT-137831 reduced alpha-SMA and CCN2 protein overexpression and collagen gel contraction. These results are consistent with the hypothesis that antioxidants or NOX1/4 inhibition may be useful in blocking profibrotic effects of TGFbeta on dermal and gingival fibroblasts and warrant consideration for further development as potential antifibrotic agents.

MeSH terms

  • Actins / metabolism*
  • Antioxidants / pharmacology*
  • Cells, Cultured
  • Connective Tissue Growth Factor / metabolism*
  • Fibroblasts / metabolism
  • Gingiva / cytology
  • Gingiva / metabolism*
  • Humans
  • NADPH Oxidase 1 / antagonists & inhibitors*
  • NADPH Oxidase 4 / antagonists & inhibitors*
  • Skin / cytology
  • Skin / metabolism*
  • Transforming Growth Factor beta1 / antagonists & inhibitors*
  • Transforming Growth Factor beta1 / physiology

Substances

  • ACTA2 protein, human
  • Actins
  • Antioxidants
  • CCN2 protein, human
  • Transforming Growth Factor beta1
  • Connective Tissue Growth Factor
  • NADPH Oxidase 1
  • NADPH Oxidase 4
  • NOX1 protein, human
  • NOX4 protein, human

Grants and funding

Our work is supported by grants from the Canadian Institutes of Health Research (MOP 77603 and 119410) and the National Sciences and Engineering Research Council to AL. KQ was the recipient of a Canadian Institutes of Health Research Summer Studentship. HMM and KQ were recipients of summer studentships from the Joint Motion Program (JuMP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.